Good MorningEquity markets fell for the 2nd day as traders assessed the latest economic data and FOMC activity. The takeaway is that inflation puts the economy on the brink of an actual recession, and the FOMC is still raising interest rates. The committee wants to ensure inflation is tamed, which will most likely trigger the recession everyone fears. Regardless, the S&P 500 is in the first inning of what could be a prolonged earnings recession that has been sparked by a decline in volume brought on by high prices and high-interest rates.
Friday's action will be critical for the market. The S&P 500 index confirms the presence of resistance at the 41,50 level, which may lead to another big sell-off. The rally may continue if the market can rebound and close even near the week's high. If not, investors should brace for another sell-off that could shave 15% to 20% off of the major indices by the start of spring. January effect or not, the outlook for S&P 500 earnings is moving lower, leading the market lower. Featured: Under $1… and Wall Street already knows about it (Ad) 
|
Consumer Staples | |
Reynolds Consumer Products (NASDAQ: REYN) share price has struggled to gain traction since the IPO, but one thing is certain. When the share prices drop below $27.75, someone in the market steps in and buys them, which is happening now. The Q1 guidance and outlook for the year are a little on the... Read the Full Story |
|
From Our Partners | | Tanker traffic through Hormuz has plunged from 110-130 daily transits to near zero, while 17% of Qatar's LNG capacity remains offline after missile strikes.
Goldman Sachs named the UK the developed economy most exposed to a jet-fuel crunch, citing critically low reserves and a gutted refining base. Dow Chemical has already doubled polyethylene prices overnight.
Garrett Goggin, CFA, CMT, points to four gold miners positioned for what comes next. | | See the four gold miners Garrett Goggin is watching now |
|
Consumer Staples | |
The price action in PepsiCo Inc. (NASDAQ: PEP) pulled back from a high recently, but this weakness in the action offers a buying opportunity in a Dividend King. PepsiCo's Q4 results prove the company's strategy continues to work and has what it takes to succeed in today's market: brand strength an... Read the Full Story |
|
Consumer Discretionary | |
It’s never too late for a curtain call.
Some stocks partied like rock stars coming off the March 2020 market bottom. As doomsday pandemic fears faded, it was the most risky (and often least profitable) companies that took center stage. Meme stocks and SPACs stole the show with some outrageo... Read the Full Story |
|
From Our Partners | | CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names distributes income every single Thursday, with payouts reported as high as $1,051 a month.
Chief Income Strategist Tim Plaehn breaks down the fund's real Thursday distribution history, how the income is generated, and how to buy it in any brokerage account. | | Watch the free presentation before this Thursday's payout |
|
Communication Services | |
Shares of The Walt Disney Company (NYSE: DIS) have been on a roller coaster ride for the last few years, leaving investors less than enthused. The latest twist in the ride, however, included the renaming of Bob Iger to the helm, a move that is getting lots of positive attention.
The question now ... Read the Full Story |
|
Consumer Discretionary | |
Looking for information about Harley Davidson and HOG stock dividend? Harley Davidson is an iconic brand with a regular dividend payment that you might want to pop into your portfolio.
By the time you reach the end of this article, you will know what you need to make an informed decision. The ta... Read the Full Story |
|
From Our Partners | | On Christmas Eve 2024, ISO New England issued an urgent plea after regional power plants failed, sending energy prices from $130.79 to over $2,000 per megawatt-hour during a bitter storm.
The grid held, barely. But rising demand from AI infrastructure and global conflicts has pushed New England's energy system closer to the edge than ever before.
See the full breakdown of what could happen next and how to prepare. | | Watch the video exposé on America's growing energy crisis now |
|
Markets | |
It's a regular occurrence. Penny stocks always dominate the top daily gainers and losers lists, often skyrocketing 50% or more in a single day. But the rapid price appreciation is usually followed by an equally dramatic crash in the price.
And you can probably picture these charts in your head. T... Read the Full Story |
|
Markets | |
The January non-farm payrolls report was much stronger than expected, and the market cheered. The takeaway, at first glance, is that the economy is doing well while inflation is cooling, but this is a dubious take on the economy.
The labor data arguably is little more than a coincident indicator ... Read the Full Story |
|
Communication Services | |
With shares having rallied nearly 30% since last November’s low, there are signs of a recovery rally truly taking off with Take-Two Interactive Software, Inc.’s (NASDAQ: TTWO) stock. Having fallen pretty much double that from its 2021 high, it’s a much-welcomed uptrend for invest... Read the Full Story |
|
Consumer Staples | |
Campbell Soup Co. (NYSE: CPB) was among the U.S. large caps that bucked the bear market of 2022. With defensive names in favor, the soup and snacks maker was also one of few S&P 500 stocks that finished the year up at least 30%.
But after reaching an intraday high of $57.78 shortly after Chri... Read the Full Story |
|
Technology | |
The S&P 500 tech sector is up 18.65% in the past month, with sector component Fortinet (NASDAQ: FTNT) gapping up 12% on February 8.
The cybersecurity specialist was the sector’s best price performer in the session, with SolarEdge Technologies Inc. (NASDAQ: SEDG), First Solar Inc. (NASD... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. | | View Today's Stock Pick |
|
